Overview

68Ga-labeled NY104 PET Imaging in Patients

Status:
Recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
This is a single arm study to evaluate the safety and biodistribution of 68Ga-labeled NY104 PET Imaging in patients with Renal Cell Carcinoma
Phase:
Early Phase 1
Details
Lead Sponsor:
Affiliated Hospital of Jiangnan University